A 63% year-over-year quarterly revenue jump is remarkable for any drug in a crowded therapeutic class, but the more revealing number from TG Therapeutics’ first-quarter print is the implied annualized trajectory: BRIUMVI is now on pace to eclipse $900 million in U.S. net product revenue before a single subcutaneous vial reaches a patient. For a therapy that launched less than three years ago into a multiple sclerosis market already saturated with anti-CD20 competition from Ocrevus and Kesimpta, that trajectory reframes TG from a one-asset commercial story into a genuine franchise build.
The guidance raise from $825–$850 million to $885–$900 million is not incremental. It reflects a structural demand signal — record new patient starts in Q1 — rather than pulled-forward quarters or favorable gross-to-net dynamics. SG&A nearly doubled year-over-year to $88 million, which is not noise; TG is deliberately front-loading commercial investment to widen the gap between BRIUMVI and Kesimpta before payer fatigue or biosimilar Ocrevus changes the competitive math. The $100 million in ring-fenced manufacturing and start-up costs for subcutaneous ublituximab adds further evidence that the company is treating SC conversion as an offensive weapon, not a defensive lifecycle move.
The capital structure choices sharpen the picture. A $500 million non-dilutive raise from Blue Owl, paired with an expanded $300 million buyback, signals management’s conviction that the stock is mispriced relative to the asset’s long-term value — and their willingness to leverage the balance sheet to press that bet. Buying back $100 million of stock at an average $29.28 in Q1 while simultaneously financing SC manufacturing is an unusually aggressive dual posture for a company still shy of $1 billion in annual revenue. It leaves thin margin for error if the ENHANCE trial or SC Phase 3 data disappoint.
The single data event that reshapes TG’s strategic position in the next six months is the ENHANCE topline readout, expected mid-year. A positive result — confirming that the Day 1/Day 15 IV dosing can be consolidated — directly reduces infusion center burden and removes the single largest real-world friction point limiting new prescriber adoption. That outcome, not the SC data, determines whether BRIUMVI’s adoption curve accelerates or plateaus heading into 2027.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
